KR20140035363A - 안정피로 치료 방법 - Google Patents

안정피로 치료 방법 Download PDF

Info

Publication number
KR20140035363A
KR20140035363A KR1020137029521A KR20137029521A KR20140035363A KR 20140035363 A KR20140035363 A KR 20140035363A KR 1020137029521 A KR1020137029521 A KR 1020137029521A KR 20137029521 A KR20137029521 A KR 20137029521A KR 20140035363 A KR20140035363 A KR 20140035363A
Authority
KR
South Korea
Prior art keywords
hydroxy
alkyl
fatty acid
hydrogen
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020137029521A
Other languages
English (en)
Korean (ko)
Inventor
류지 우에노
Original Assignee
수캄포 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 수캄포 아게 filed Critical 수캄포 아게
Publication of KR20140035363A publication Critical patent/KR20140035363A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020137029521A 2011-04-07 2012-04-06 안정피로 치료 방법 Withdrawn KR20140035363A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161472875P 2011-04-07 2011-04-07
US61/472,875 2011-04-07
PCT/JP2012/060094 WO2012137987A1 (en) 2011-04-07 2012-04-06 Method for treating asthenopia

Publications (1)

Publication Number Publication Date
KR20140035363A true KR20140035363A (ko) 2014-03-21

Family

ID=46966570

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137029521A Withdrawn KR20140035363A (ko) 2011-04-07 2012-04-06 안정피로 치료 방법

Country Status (8)

Country Link
US (1) US8889735B2 (cg-RX-API-DMAC10.html)
EP (1) EP2694077A4 (cg-RX-API-DMAC10.html)
JP (1) JP2014510022A (cg-RX-API-DMAC10.html)
KR (1) KR20140035363A (cg-RX-API-DMAC10.html)
CN (1) CN103561748A (cg-RX-API-DMAC10.html)
CA (1) CA2830626A1 (cg-RX-API-DMAC10.html)
TW (1) TW201247206A (cg-RX-API-DMAC10.html)
WO (1) WO2012137987A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
KR20180058758A (ko) 2015-09-22 2018-06-01 그레이버그 비젼, 인크. 안구 장애의 치료를 위한 화합물 및 조성물
MX2019011242A (es) 2017-03-23 2020-01-21 Graybug Vision Inc Farmacos y composiciones para el tratamiento de trastornos oculares.
MX2019013363A (es) 2017-05-10 2020-01-13 Graybug Vision Inc Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica.

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380709A (en) 1987-01-28 1995-01-10 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5591887A (en) 1987-04-30 1997-01-07 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
CA1324129C (en) 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
US5151444B1 (en) 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
US5166178B1 (en) 1987-09-18 1998-07-21 R Tech Ueno Ltd Ocular hypotensive agents
US5236907A (en) 1988-10-01 1993-08-17 R-Tech Ueno Ltd. Ocular hypotensive agents
GB2209939B (en) 1987-09-18 1992-01-02 R Tech Ueno Ltd The use of 13,14-dihydro-15-keto-prostaglandins as ocular hypotensive agents
US5194429A (en) 1988-10-01 1993-03-16 K.K. Ueno Seiyaku Oyo Kenkyujo Ocular hypotensive agents
TW249226B (cg-RX-API-DMAC10.html) 1990-04-04 1995-06-11 Aderk Ueno Kk
CA2065889C (en) 1991-10-02 2002-08-27 Tetsuya Sugiyama Increasing the choroidal blood flow
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JP3625946B2 (ja) * 1995-03-10 2005-03-02 株式会社アールテック・ウエノ 視神経障害改善剤
TW420611B (en) * 1995-03-10 2001-02-01 R Tech Ueno Ltd Pharmaceutical composition containing prostanoic acid compounds for the treatment of optic nerve disorder
KR19990036322A (ko) 1996-06-10 1999-05-25 류지 우에노 엔도텔린길항제
US6291466B1 (en) * 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
SE0002211D0 (sv) * 2000-06-13 2000-06-13 Synphora Ab Methods and compositions for prevention of myopia
BR0205932A (pt) * 2001-08-23 2004-02-17 Sucampo Ag Método e composição para tratamento de hipertensão ocular e glaucoma
WO2008023784A1 (fr) * 2006-08-25 2008-02-28 Showa University Agent pour l'amélioration d'un trouble de la circulation ophtalmique
KR101405823B1 (ko) * 2007-12-24 2014-06-12 주식회사 케이티앤지생명과학 녹내장의 치료 및 예방을 위한 약제 조성물

Also Published As

Publication number Publication date
WO2012137987A1 (en) 2012-10-11
EP2694077A4 (en) 2015-01-21
CN103561748A (zh) 2014-02-05
US20120259008A1 (en) 2012-10-11
TW201247206A (en) 2012-12-01
EP2694077A1 (en) 2014-02-12
US8889735B2 (en) 2014-11-18
JP2014510022A (ja) 2014-04-24
CA2830626A1 (en) 2012-10-11

Similar Documents

Publication Publication Date Title
JP5686819B2 (ja) 黄斑浮腫を処置するための医薬組成物
US20120263803A1 (en) Aqueous ophthalmic composition
US8889735B2 (en) Method for treating asthenopia
TWI403324B (zh) 醫藥組成物
KR101118935B1 (ko) 안과용 조성물
US20140066506A1 (en) Method for treating macular degeneration
US20050014837A1 (en) Method for treating ocular hypertension and glaucoma
JP2004538306A (ja) 高眼圧症および緑内障の処置
KR20040029012A (ko) 안내압항진 및 녹내장 치료용 방법 및 조성물
HK1181675A (en) Pharmaceutical composition for treating macular edema
AU2002255346A1 (en) Method for treatingocular hypertension and glaucoma

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20131106

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid